Bloomberg Originals
@business·5.1M subscribers·49.5K videos
GlaxoSmithKline CEO: More Transparency Is Needed in Drug Pricing
Posted
November 4, 2015
Views
1,233
Likes
9
Comments
1
Engagement
November 4, 2015
1,233
9
1
0.81%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
10:20Now PlayingNov. 3 -- Andrew Witty, GlaxoSmithKline's chief executive officer, discusses the company's growth prospects, the Pfizer-Allergan talks and drug pricing. He speaks with Bloomberg's Erik Schatzker and Cynthia Koons on "What'd You Miss?"
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
